CoChat

New insights into RAS biology reinvigorate interest in mathematical modeling of RAS signaling

Open access
Erickson, Keesha E., Rukhlenko, Oleksii S., Posner, Richard G., Hlavacek, William S., Kholodenko, Boris N. · 2019 · Seminars in Cancer Biology
Cited by 19

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Abstract

RAS is the most frequently mutated gene across human cancers, but developing inhibitors of mutant RAS has proven to be challenging. Given the difficulties of targeting RAS directly, drugs that impact the other components of pathways where mutant RAS operates may potentially be effective. However, the system-level features, including different localizations of RAS isoforms, competition between downstream effectors, and interlocking feedback and feed-forward loops, must be understood to fully grasp the opportunities and limitations of inhibiting specific targets. Mathematical modeling can help us discern the system-level impacts of these features in normal and cancer cells. New technologies enable the acquisition of experimental data that will facilitate development of realistic models of oncogenic RAS behavior. In light of the wealth of empirical data accumulated over decades of study and the advancement of experimental methods for gathering new data, modelers now have the opportunity to advance progress toward realization of targeted treatment for mutant RAS-driven cancers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.semcancer.2018.02.008

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Research works printed but not linked: 143

  1. Barbacid, 1987, Ras genes, Annu. Rev. Biochem., 56, 779, 10.1146/annurev.bi.56.070187.004023 · DOI · Paper page
  2. Colicelli, 2004, Human RAS superfamily proteins and related GTPases, Sci. STKE, 250, RE13
  3. Novotny, 2017, Farnesyltransferase-mediated delivery of a covalent inhibitor overcomes alternative prenylation to mislocalize K‐Ras, ACS Chem. Biol., 12, 1956, 10.1021/acschembio.7b00374 · DOI · Paper page
  4. Ho, 2017, An open-label, phase II study of tipifarnib for the treatment of HRAS mutant solid tumors, including squamous cell carcinomas of the head and neck, J. Clin. Oncol., 35, 10.1200/JCO.2017.35.15_suppl.TPS2618 · doi:10.1200/jco.2017.35.15_suppl.tps2618
  5. Pilz, 1997, A decrease in the intracellular guanosine concentration is necessary for granulocytic differentiation of HL-60Cells, but growth cessation and differentiation are not associated with a change in the activation state of ras, the transforming principle of, Cell Growth Differ., 8, 53
  6. Allin, 2001, Monitoring the GAP catalyzed H-Ras GTPase reaction at atomic resolution in real time, Proc. Natl. Acad. Sci., 98, 7754, 10.1073/pnas.131549798 · DOI
  7. Allin, 2001, Ras catalyzes GTP hydrolysis by shifting negative charges from γ-to phosphate as revealed by time-resolved FTIR difference spectroscopy, Biochemistry, 40, 3037, 10.1021/bi0017024 · DOI
  8. Ahmadian, 1997, Confirmation of the arginine-finger hypothesis for the GAP-stimulated GTP-hydrolysis reaction of Ras, Nat. Struct. Mol. Biol., 4, 686, 10.1038/nsb0997-686 · DOI · Paper page
  9. Vigil, 2010, Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?, Nat. Rev. Cancer, 10, 842, 10.1038/nrc2960 · DOI · Paper page
  10. Denhardt, 1996, Signal-transducing protein phosphorylation cascades mediated by Ras/Rho proteins in the mammalian cell: the potential for multiplex signalling, Biochem. J., 318, 729, 10.1042/bj3180729 · DOI · Paper page
  11. McLaughlin, 2013, The RasGAP gene, RASAL2, is a tumor and metastasis suppressor, Cancer Cell, 24, 365, 10.1016/j.ccr.2013.08.004 · DOI · Paper page
  12. Sung, 2016, Inactivation of RASA1 promotes melanoma tumorigenesis via R-Ras activation, Oncotarget, 7, 23885, 10.18632/oncotarget.8127 · DOI
  13. Markevich, 2004, Signal processing at the Ras circuit: what shapes Ras activation patterns?, Syst. Biol. (Stevenage), 1, 104, 10.1049/sb:20045003 · DOI · Paper page
  14. Neel, 2011, The RalGEF-Ral effector signaling network: the road less traveled for anti-Ras drug discovery, Genes Cancer, 2, 275, 10.1177/1947601911407329 · DOI · Paper page
  15. Shankar, 2016, KRAS engages AGO2 to enhance cellular transformation, Cell Rep., 14, 1448, 10.1016/j.celrep.2016.01.034 · DOI · Paper page
  16. Joneson, 1997, Ras effectors and their role in mitogenesis and oncogenesis, J. Mod. Med., 75, 587
  17. Castellano, 2011, Functional specificity of ras isoforms: so similar but so different, Genes Cancer, 2, 216, 10.1177/1947601911408081 · DOI · Paper page
  18. Vu, 2016, Targeting mutant NRAS signaling pathways in melanoma, Pharmacol. Res., 107, 111, 10.1016/j.phrs.2016.03.007 · DOI
  19. T. Cancer Genome Atlas Research Network, 2013, The cancer genome atlas pan-cancer analysis project, Nat. Genet., 45, 1113, 10.1038/ng.2764 · DOI · Paper page
  20. Stites, 2012, Mechanistic modeling to investigate signaling by oncogenic Ras mutants, Wiley Interdiscip. Rev. Syst. Biol. Med., 4, 117, 10.1002/wsbm.156 · DOI
  21. Brightman, 2000, Differential feedback regulation of the MAPK cascade underlies the quantitative differences in EGF and NGF signalling in PC12 cells, FEBS Lett., 482, 169, 10.1016/S0014-5793(00)02037-8 · DOI · Paper page
  22. Schoeberl, 2002, Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors, Nat. Biotechnol., 20, 370, 10.1038/nbt0402-370 · DOI · Paper page
  23. Kholodenko, 1999, Quantification of short term signaling by the epidermal growth factor receptor, J. Biol. Chem., 274, 30169, 10.1074/jbc.274.42.30169 · DOI · Paper page
  24. Orton, 2005, Computational modelling of the receptor-tyrosine-kinase-activated MAPK pathway, Biochem. J., 392, 249, 10.1042/BJ20050908 · DOI · Paper page
  25. Stites, 2007, Network analysis of oncogenic ras activation in cancer, Science, 318, 463, 10.1126/science.1144642 · DOI · Paper page
  26. Orton, 2009, Computational modelling of cancerous mutations in the EGFR/ERK signalling pathway, BMC Syst. Biol., 3, 100, 10.1186/1752-0509-3-100 · DOI
  27. Stites, 2015, Cooperation between noncanonical ras network mutations, Cell Rep., 10, 307, 10.1016/j.celrep.2014.12.035 · DOI · Paper page
  28. Kholodenko, 2010, Signalling ballet in space and time, Nat. Rev. Mol. Cell Biol., 11, 414, 10.1038/nrm2901 · DOI · Paper page
  29. Buhrman, 2010, Allosteric modulation of Ras positions Q61 for a direct role in catalysis, Proc. Natl. Acad. Sci., 107, 4931, 10.1073/pnas.0912226107 · DOI · Paper page
  30. Ihle, 2012, Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome, J. Natl. Cancer Inst., 104, 228, 10.1093/jnci/djr523 · DOI · Paper page
  31. Margarit, 2003, Structural evidence for feedback activation by Ras·GTP of the Ras-specific nucleotide exchange factor SOS, Cell, 112, 685, 10.1016/S0092-8674(03)00149-1 · DOI · Paper page
  32. Gremer, 2010, Duplication of Glu 37 in the switch I region of HRAS impairs effector/GAP binding and underlies Costello syndrome by promoting enhanced growth factor-dependent MAPK and AKT activation, Hum. Mol. Genet., 19, 790, 10.1093/hmg/ddp548 · DOI
  33. Cirstea, 2013, Diverging gain-of-function mechanisms of two novel KRAS mutations associated with Noonan and cardio-facio-cutaneous syndromes, Hum. Mol. Genet., 22, 262, 10.1093/hmg/dds426 · DOI · Paper page
  34. Denayer, 2008, Mutation analysis in costello syndrome: functional and structural characterization of the HRAS p.Lys117Arg mutation, Hum. Mutat., 29, 232, 10.1002/humu.20616 · DOI
  35. Kenney, 2017, A computational panel of pathological RAS mutants with implications for personalized medicine and genetic medicine, bioRxiv
  36. Stites, 2014, Differences in sensitivity to EGFR inhibitors could be explained by described biochemical differences between oncogenic Ras mutants, bioRxiv
  37. Kiel, 2014, Structure-energy-based predictions and network modelling of RASopathy and cancer missense mutations, Mol. Syst. Biol., 10, 727, 10.1002/msb.20145092 · DOI · Paper page
  38. Baldwin, 2009, NMR spectroscopy brings invisible protein states into focus, Nat. Chem. Biol., 5, 808, 10.1038/nchembio.238 · DOI · Paper page
  39. Mittermaier, 2009, Observing biological dynamics at atomic resolution using NMR, Trends Biochem. Sci., 601, 10.1016/j.tibs.2009.07.004 · DOI · Paper page
  40. Theillet, 2012, Cell signaling, post-translational protein modifications and NMR spectroscopy, J. Biomol. NMR, 54, 217, 10.1007/s10858-012-9674-x · DOI · Paper page
  41. Hause, 2012, Comprehensive binary interaction mapping of SH2 domains via fluorescence polarization reveals novel functional diversification of ErbB receptors, PLoS One, 7, e44471, 10.1371/journal.pone.0044471 · DOI
  42. Kaushansky, 2010, Quantifying protein-protein interactions in high throughput using protein domain microarrays, Nat. Protoc., 5, 773, 10.1038/nprot.2010.36 · DOI · Paper page
  43. Vincentelli, 2015, Quantifying domain-ligand affinities and specificities by high-throughput holdup assay, Nat. Methods, 12, 787, 10.1038/nmeth.3438 · DOI · Paper page
  44. Kowalsky, 2016, Determination of binding affinity upon mutation for type I dockerin-cohesion complexes from Clostridium thermocellum and Clostridium cellulolyticum using deep sequencing, Proteins Struct. Funct. Bioinformatics, 84, 1914, 10.1002/prot.25175 · DOI
  45. Stites, 2015, Use of mechanistic models to integrate and analyze multiple proteomic datasets, Biophys. J., 108, 1819, 10.1016/j.bpj.2015.02.030 · DOI
  46. Kiel, 2014, Quantification of ErbB network proteins in three cell types using complementary approaches identifies cell-general and cell-type-specific signaling proteins, J. Proteome Res., 13, 300, 10.1021/pr400878x · DOI
  47. Shi, 2012, Antibody-free, targeted mass-spectrometric approach for quantification of proteins at low picogram per milliliter levels in human plasma/serum, Proc. Natl. Acad. Sci., 109, 15395, 10.1073/pnas.1204366109 · DOI · Paper page
  48. Shi, 2016, Conservation of protein abundance patterns reveals the regulatory architecture of the EGFR-MAPK pathway, Sci. Signal., 9, 10.1126/scisignal.aaf0891 · DOI · Paper page
  49. Sudhir, 2011, Phosphoproteomics identifies oncogenic Ras signaling targets and their involvement in lung adenocarcinomas, PLoS One, 6, 10.1371/journal.pone.0020199 · DOI
  50. Gnad, 2013, Systems-wide analysis of K-Ras, Cdc42, and PAK4 signaling by quantitative phosphoproteomics, Mol. Cell. Proteomics, 12, 2070, 10.1074/mcp.M112.027052 · DOI
  51. Moritz, 2010, Akt-RSK-S6 kinase signaling networks activated by oncogenic receptor tyrosine kinases, Sci. Signal., 3, 10.1126/scisignal.2000998 · DOI · Paper page
  52. Shalem, 2014, Genome-scale CRISPR-Cas9 knockout screening in human cells, Science, 343, 84, 10.1126/science.1247005 · DOI · Paper page
  53. Wang, 2014, Genetic screens in human cells using the CRISPR-Cas9 system, Science, 343, 80, 10.1126/science.1246981 · DOI · Paper page
  54. Cong, 2013, Multiplex genome engineering using CRISPR/Cas systems, Science, 339, 819, 10.1126/science.1231143 · DOI · Paper page
  55. Mali, 2013, RNA-guided human genome engineering via Cas9, Science, 339, 823, 10.1126/science.1232033 · DOI · Paper page
  56. Konermann, 2015, Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex, Nature, 517, 583, 10.1038/nature14136 · DOI · Paper page
  57. Young, 2013, SHOC2, and SCRIB complex coordinates ERK pathway activation with polarity and tumorigenic growth, Mol. Cell, 52, 679, 10.1016/j.molcel.2013.10.004 · DOI
  58. Harvey, 2008, The spread of ras activity triggered by activation of a single dendritic spine, Science, 321, 136, 10.1126/science.1159675 · DOI · Paper page
  59. Kholodenko, 2009, Spatially distributed cell signalling, FEBS Lett., 583, 4006, 10.1016/j.febslet.2009.09.045 · DOI
  60. Tsyganov, 2012, The topology design principles that determine the spatiotemporal dynamics of G-protein cascades, Mol. Biosyst., 8, 730, 10.1039/c2mb05375f · DOI
  61. Muñoz-García, 2010, Signalling over a distance: gradient patterns and phosphorylation waves within single cells, Biochem. Soc. Trans., 38, 10.1042/BST0381235 · DOI
  62. Verissimo, 2016, Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening, Elife, e18489, 10.7554/eLife.18489 · DOI · Paper page
  63. Harvey, 2008, A genetically encoded fluorescent sensor of ERK activity, Proc. Natl. Acad. Sci., 105, 19264, 10.1073/pnas.0804598105 · DOI · Paper page
  64. Albeck, 2013, Frequency-modulated pulses of ERK activity transmit quantitative proliferation signals, Mol. Cell, 49, 249, 10.1016/j.molcel.2012.11.002 · DOI · Paper page
  65. Ryu, 2015, Frequency modulation of ERK activation dynamics rewires cell fate, Mol. Syst. Biol., 11, 10.15252/msb.20156458 · DOI · Paper page
  66. Vandame, 2014, Optimization of ERK activity biosensors for both ratiometric and lifetime FRET measurements, Sensors, 14, 1140, 10.3390/s140101140 · doi:10.3390/s140101140
  67. Regot, 2014, High-sensitivity measurements of multiple kinase activities in live single cells, Cell, 157, 1724, 10.1016/j.cell.2014.04.039 · DOI · Paper page
  68. Toettcher, 2013, Using optogenetics to interrogate the dynamic control of signal transmission by the Ras/Erk module, Cell, 155, 1422, 10.1016/j.cell.2013.11.004 · DOI · Paper page
  69. Levskaya, 2009, Spatiotemporal control of cell signalling using a light- switchable protein interaction, Nature, 461, 997, 10.1038/nature08446 · DOI · Paper page
  70. Druker, 1996, Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells, Nat. Med., 2, 561, 10.1038/nm0596-561 · DOI · Paper page
  71. Deininger, 2003, Specific targeted therapy of chronic myelogenous leukemia with imatinib, Pharmacol. Rev., 55, 401, 10.1124/pr.55.3.4 · DOI · Paper page
  72. Flaherty, 2010, Inhibition of mutated, activated BRAF in metastatic melanoma, N. Engl. J. Med., 363, 809, 10.1056/NEJMoa1002011 · DOI · Paper page
  73. Davies, 2002, Mutations of the BRAF gene in human cancer, Nature, 417, 949, 10.1038/nature00766 · DOI · Paper page
  74. Swaika, 2014, Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma, Drug Des Dev. Ther., 4, 775
  75. Cohen, 2003, FDA drug approval summary gefitinib (ZD1839) (Iressa) tablets, Oncologist, 8, 303, 10.1634/theoncologist.8-4-303 · DOI · Paper page
  76. Khozin, 2014, U. S. Food and drug administration approval summary: erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations, Oncologist, 21, 774, 10.1634/theoncologist.2014-0089 · DOI · Paper page
  77. Keating, 2014, Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer, Drugs, 74, 207, 10.1007/s40265-013-0170-8 · DOI
  78. Wu, 2015, FDA-approved small-molecule kinase inhibitors, Trends Pharmacol. Sci., 36, 422, 10.1016/j.tips.2015.04.005 · DOI · Paper page
  79. Stuhlmiller, 2015, Inhibition of lapatinib-Induced kinome reprogramming in ERBB2-positive breast cancer by targeting BET family bromodomains, Cell Rep., 11, 390, 10.1016/j.celrep.2015.03.037 · DOI · Paper page
  80. Liu, 2016, Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells, Oncogene, 7, 9135
  81. Robert, 2015, Improved overall survival in melanoma with combined dabrafenib and trametinib, N. Engl. J. Med., 372, 10.1056/NEJMoa1412690 · DOI · Paper page
  82. Smith, 2007, 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial, Lancet, 369, 29, 10.1016/S0140-6736(07)60028-2 · DOI · Paper page
  83. Bang, 2010, Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial, Lancet, 376, 687, 10.1016/S0140-6736(10)61121-X · DOI · Paper page
  84. Ostrem, 2013, K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions, Nature, 503, 548, 10.1038/nature12796 · DOI · Paper page
  85. Papke, 2016, Identification of pyrazolopyridazinones as PDEδ inhibitors, Nat. Commun., 7, 11360, 10.1038/ncomms11360 · DOI · Paper page
  86. Dekker, 2010, Small-molecule inhibition of APT1 affects Ras localization and signaling, Nat. Chem. Biol., 6, 449, 10.1038/nchembio.362 · DOI · Paper page
  87. Najumudeen, 2016, Cancer stem cell drugs target K-ras signaling in a stemness context, Oncogene, 35, 5248, 10.1038/onc.2016.59 · DOI
  88. Holohan, 2013, Cancer drug resistance: an evolving paradigm, Nat. Rev. Cancer, 13, 714, 10.1038/nrc3599 · DOI · Paper page
  89. Pao, 2005, Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain, PLoS Med., 2, e73, 10.1371/journal.pmed.0020073 · DOI · Paper page
  90. Aplin, 2011, Mechanisms of resistance to RAF inhibitors in melanoma, J. Invest. Dermatol., 131, 1817, 10.1038/jid.2011.147 · DOI
  91. Montagut, 2008, Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma, Cancer Res., 68, 4853, 10.1158/0008-5472.CAN-07-6787 · DOI · Paper page
  92. Iadevaia, 2010, Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis, Cancer Res., 70, 6704, 10.1158/0008-5472.CAN-10-0460 · DOI · Paper page
  93. Waters, 1996, Insulin and epidermal growth factor receptors regulate distinct pools of Grb2-SOS in the control of ras activation, J. Biol. Chem., 271, 18224, 10.1074/jbc.271.30.18224 · DOI
  94. Hennig, 2016, Feedback activation of neurofibromin terminates growth factor-induced Ras activation, Cell Commun. Signal., 14, 10.1186/s12964-016-0128-z · DOI · Paper page
  95. Catalanotti, 2009, A Mek1–Mek2 heterodimer determines the strength and duration of the Erk signal, Nat. Struct. Mol. Biol., 16, 294, 10.1038/nsmb.1564 · DOI · Paper page
  96. Brunet, 1994, Growth factor-stimulated MAP kinase induces rapid retrophosphorylation and inhibition of MAP kinase kinase (MEK1), FEBS Lett., 346, 299, 10.1016/0014-5793(94)00475-7 · DOI
  97. Corbalan-Garcia, 1996, Identification of the mitogen-activated protein kinase phosphorylation sites on human sos1 that regulate interaction with Grb2, Mol. Cell. Biol., 16, 5674, 10.1128/MCB.16.10.5674 · DOI · Paper page
  98. Chen, 1996, SOS phosphorylation and disassociation of the Grb2-SOS complex by the ERK and JNK signaling pathways, J. Biol. Chem., 271, 6328, 10.1074/jbc.271.11.6328 · DOI · Paper page
  99. Waters, 1995, Desensitization of ras activation by a feedback disassociation of the SOS-Grb2 complex, J. Biol. Chem., 270, 20883, 10.1074/jbc.270.36.20883 · DOI · Paper page
  100. Dougherty, 2005, Regulation of Raf-1 by direct feedback phosphorylation, Mol. Cell, 17, 215, 10.1016/j.molcel.2004.11.055 · DOI · Paper page
  101. Ritt, 2010, Impact of feedback phosphorylation and raf heterodimerization on normal and mutant B-Raf signaling, Mol. Cell Biol., 30, 806, 10.1128/MCB.00569-09 · DOI · Paper page
  102. Gross, 2001, Mammalian sprouty proteins inhibit cell growth and differentiation by preventing ras activation, J. Biol. Chem., 276, 46460, 10.1074/jbc.M108234200 · DOI · Paper page
  103. Lim, 2000, Sprouty proteins are targeted to membrane ruffles upon growth factor receptor tyrosine kinase activation, J. Biol. Chem., 275, 32837, 10.1074/jbc.M002156200 · DOI
  104. Masoumi-Moghaddam, 2014, The developing story of Sprouty and cancer, Cancer Metastasis Rev., 33, 695, 10.1007/s10555-014-9497-1 · DOI · Paper page
  105. Mason, 2006, Sprouty proteins: multifaceted negative-feedback regulators of receptor tyrosine kinase signaling, Trends Cell Biol., 16, 45, 10.1016/j.tcb.2005.11.004 · DOI · Paper page
  106. Rubin, 2005, Phosphorylation of carboxyl-terminal tyrosines modulates the specificity of sprouty-2 inhibition of different signaling pathways, J. Biol. Chem., 280, 9735, 10.1074/jbc.M408308200 · DOI
  107. Tsavachidou, 2004, SPRY2 is an inhibitor of the Ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant, Cancer Res., 64, 5556, 10.1158/0008-5472.CAN-04-1669 · DOI · Paper page
  108. Tefft, 2002, mSprouty2 inhibits FGF10-activated MAP kinase by differentially binding to upstream target proteins, Am. J. Physiol. Lung Cell Mol. Physiol., 283, L700, 10.1152/ajplung.00372.2001 · DOI · Paper page
  109. Boykevisch, 2006, Regulation of Ras signaling dynamics by sos-mediated positive feedback, Curr. Biol., 16, 2173, 10.1016/j.cub.2006.09.033 · DOI
  110. Freedman, 2006, A Ras-induced conformational switch in the Ras activator Son of sevenless, Proc. Natl. Acad. Sci., 103, 16692, 10.1073/pnas.0608127103 · DOI · Paper page
  111. Sondermann, 2004, Structural analysis of autoinhibition in the Ras activator son of sevenless, Cell, 119, 393, 10.1016/j.cell.2004.10.005 · DOI · Paper page
  112. Lun, 2017, Influence of node abundance on signaling network state and dynamics analyzed by mass cytometry, Nat. Biotechnol., 35, 164, 10.1038/nbt.3770 · DOI
  113. Birtwistle, 2012, Emergence of bimodal cell population responses from the interplay between analog single-cell signaling and protein expression noise, BMC Syst. Biol., 6, 109, 10.1186/1752-0509-6-109 · DOI · Paper page
  114. Dobrzynski, 2014, Nonlinear signalling networks and cell- to-cell variability transform external signals into broadly distributed or bimodal responses, J. R. Soc. Interface, 11, 20140383, 10.1098/rsif.2014.0383 · DOI
  115. Dobrzynski, 2012, Bimodal protein distributions in heterogeneous oscillating systems, Lect. Notes Comput. Sci., 17, 10.1007/978-3-642-33636-2_3 · DOI
  116. Shin, 2008, Positive- and negative-feedback regulations coordinate the dynamic behavior of the Ras-Raf-MEK-ERK signal transduction pathway, J. Cell Sci., 122, 425, 10.1242/jcs.036319 · DOI · Paper page
  117. Bluthgen, 2006, Effects of sequestration on signal transduction cascades, FEBS J., 273, 895, 10.1111/j.1742-4658.2006.05105.x · DOI
  118. Markevich, 2004, Signaling switches and bistability arising from multisite phosphorylation in protein kinase cascades, J. Cell Biol., 164, 353, 10.1083/jcb.200308060 · DOI · Paper page
  119. Muller, 2001, C-TAK1 regulates ras signaling by phosphorylating the MAPK scaffold, KSR1, Mol. Cell, 8, 983, 10.1016/S1097-2765(01)00383-5 · DOI · Paper page
  120. Lemmon, 2010, Cell signaling by receptor tyrosine kinases, Cell, 1117, 10.1016/j.cell.2010.06.011 · DOI · Paper page
  121. Markevich, 2006, Long-range signaling by phosphoprotein waves arising from bistability in protein kinase cascades, Mol. Syst. Biol., 2, 61, 10.1038/msb4100108 · DOI
  122. Prior, 2012, Ras trafficking, localization and compartmentalized signalling, Semin. Cell Dev. Biol., 23, 145, 10.1016/j.semcdb.2011.09.002 · DOI · Paper page
  123. Fivaz, 2005, Reversible intracellular translocation of KRas but not HRas in hippocampal neurons regulated by Ca 2, J. Cell Biol., 170, 429, 10.1083/jcb.200409157 · DOI · Paper page
  124. Kranenburg, 2001, Regulating c-Ras function: cholesterol depletion affects caveolin association, GTP loading, and signaling, Curr. Biol., 11, 1880, 10.1016/S0960-9822(01)00582-6 · DOI
  125. Matallanas, 2006, Distinct utilization of effectors and biological outcomes resulting from site-specific ras activation: ras functions in lipid rafts and golgi complex are dispensable for proliferation and transformation, Mol. Cell Biol., 26, 100, 10.1128/MCB.26.1.100-116.2006 · DOI · Paper page
  126. Nakhaeizadeh, 2016, The RAS-effector interface: isoform-specific differences in the effector binding regions, PLoS One, 11, e0167145, 10.1371/journal.pone.0167145 · DOI · Paper page
  127. Fey, 2015, Signaling pathway models as biomarkers: patient-specific simulations of JNK activity predict the survival of neuroblastoma patients, Sci. Signal., 8, ra130, 10.1126/scisignal.aab0990 · DOI · Paper page
  128. Chmielecki, 2011, Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling, Sci. Transl. Med., 3, 10.1126/scitranslmed.3002356 · DOI · Paper page
  129. Gallaher, 2018, Spatial heterogeneity and evolutionary dynamics modulate time to recurrence in continuous and adaptive cancer therapies, Cancer Res., 10.1158/0008-5472.CAN-17-2649 · DOI · Paper page
  130. Enriquez-Navas, 2016, Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer, Sci. Transl. Med., 8, 10.1126/scitranslmed.aad7842 · DOI · Paper page
  131. Shain, 2015, A multidisciplinary model predicts clinical response in relapsed multiple myeloma, Blood, 126, 501, 10.1182/blood.V126.23.501.501 · doi:10.1182/blood.v126.23.501.501
  132. Altrock, 2016, Mathematical modeling of erythrocyte chimerism informs genetic intervention strategies for sickle cell disease, Am. J. Hematol., 91, 931, 10.1002/ajh.24449 · DOI · Paper page
  133. Serre, 2016, Mathematical modeling of cancer immunotherapy and its synergy with radiotherapy, Cancer Res., 76, 4931, 10.1158/0008-5472.CAN-15-3567 · DOI · Paper page
  134. Kim, 2016, Phase i trials in melanoma: a framework to translate preclinical findings to the clinic, Eur. J. Cancer., 67, 213, 10.1016/j.ejca.2016.07.024 · DOI
  135. Chakrabarti, 2017, Pharmacokinetics and drug interactions determine optimum combination strategies in computational models of cancer evolution, Cancer Res., 77, 3908, 10.1158/0008-5472.CAN-16-2871 · DOI
  136. Kolch, 2015, The dynamic control of signal transduction networks in cancer cells, Nat. Rev. Cancer, 15, 515, 10.1038/nrc3983 · DOI · Paper page
  137. Lenzen, 1998, Kinetic analysis by fluorescence of the interaction between ras and the catalytic domain of the guanine nucleotide exchange factor Cdc25 mm, Biochemistry, 2960, 7420, 10.1021/bi972621j · DOI · Paper page
  138. Eccleston, 1991, Fluorescence approaches to the study of the p21ras GTPase mechanism, Biochem. Soc. Trans., 19, 432, 10.1042/bst0190432 · DOI
  139. Wey, 2013, Kinetic mechanisms of mutation-dependent harvey Ras activation and their relevance for the development of costello syndrome, Biochemistry, 52, 8465, 10.1021/bi400679q · DOI · Paper page
  140. Donovan, 1602, GTPase activating proteins: critical regulators of intracellular signaling, Biochim. Biophys. Acta, 2002, 23
  141. Bollag, 1996, Biochemical characterization of a novel KRAS insertion mutation from a human leukemia, J. Biol. Chem., 271, 32491, 10.1074/jbc.271.51.32491 · DOI · Paper page
  142. John, 1988, Biochemical properties of Ha-ras encoded p21 mutants and mechanism of the autophosphorylation reaction, J. Biol. Chem., 263, 11792, 10.1016/S0021-9258(18)37854-2 · DOI · Paper page
  143. Smith, 2017, Evolution of AF6-RAS association and its implications in mixed-lineage leukemia, Nat. Commun., 8, 1099, 10.1038/s41467-017-01326-5 · DOI · Paper page

Cited by

See all 19

Metadata

Authors
Erickson, K. E., Rukhlenko, O. S., Posner, R. G., Hlavacek, W. S., & Kholodenko, B. N.
Venue
Seminars in Cancer Biology
Publisher
Elsevier BV
Published
2019-02
Volume
54
Pages
162-173
ISSN
1044-579X (ISSN-L)
OpenAlex
W2790200234
Cited by
19
References
38
FWCI
0.71
Type
journal article
Language
en
Open access
bronze
Licence
Funders
  • Joint Design of Advanced Computing Solutions for Cancer
  • National Institutes of Health (GM111510)
  • NIH/NCI (CA197398)
  • European Union grants SmartNanoTox (686098)
  • NanoCommons (731032)
  • MSCA-IF-2016 SAMNets (750688)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: New insights into RAS biology reinvigorate interest in mathematical modeling of RAS signaling. https://app.cochat.ai/papers/10.1016/j.semcancer.2018.02.008
The paper
Erickson, K. E., Rukhlenko, O. S., Posner, R. G., Hlavacek, W. S., & Kholodenko, B. N. (2019). New insights into RAS biology reinvigorate interest in mathematical modeling of RAS signaling. Seminars in Cancer Biology. https://doi.org/10.1016/j.semcancer.2018.02.008

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.